Inova Health Care Services

Inova Health Care Services, doing business as Inova Fairfax Hospital, is a nonprofit hospital and healthcare system subsidiary of Inova Health System Foundation headquartered in Fairfax, Virginia, that operates as a prime contractor and grant recipient providing biospecimen collection, laboratory and testing services, blood products, sterile processing, clinical research support, and patient hospitalization services to federal agencies. The organization competes in full-and-open procurements without set-aside designations and operates primarily as a prime (62% of recent awards) with selective subcontractor engagement (38% of awards).

Inova's customer concentration spans 32 federal agencies with pronounced depth in intramural research and military health services. The National Heart Lung and Blood Institute leads by award count with 31 awards ($6.8 million combined potential value) anchored in graft sample and data collection protocols; the Defense Health Agency places 21 awards ($11.2 million combined potential value) primarily for blood and blood products supply to Fort Belvoir Community Hospital and sterile processing services; and the Department of State Bureau of Medical Services concentrates most potential dollars with 4 awards carrying $19.2 million in combined potential value for medical instruments and supplies. The National Highway Traffic Safety Administration holds a single-award Indefinite Delivery Contract worth $2.7 million for Crash Injury Research and Engineering Network (CIREN) enrollment and crash injury research through September 2028, under which Inova placed a $2.7 million delivery order in February 2025 and invoiced $434 thousand in FY2023 and $440 thousand in FY2024 across roughly 1.7–1.8 FTEs with no subcontractor labor. Representative prime contracts include a $1.9 million delivery order from the Department of State Bureau of Medical Services for medical instruments and supplies (March 2022–September 2023), a $762 thousand firm fixed-price purchase order from the National Heart Lung and Blood Institute for multi-scale phenotyping of heart failure (awarded September 2024, terminated for convenience March 2025), a $639 thousand contract with NHLBI for support services to the Pulmonary Vascular Program running through November 2026, and a $1.8 million NIH Clinical Center purchase order for patient hospitalization and care coverage (awarded October 2023, completed June 2024).

Inova holds a primary vehicle position on the NHTSA CIREN single-award IDC ($2.2 million ceiling through August 2027) and subcontracts on federal research initiatives under multiple prime grantees including the Henry M. Jackson Foundation for the Advancement of Military Medicine, Georgetown University, Stanford University, Vanderbilt University Medical Center, and Columbia University in support of oncology biospecimen banking, cardiovascular research, gynecologic cancer center operations, and HIV/AIDS prevention services. Activity has grown from 11 awards in 2022 to a peak of 22 in 2024, with 20 awards in 2025 and 11 in 2026 year-to-date; the recompete cliff shows seven awards (combined potential value $3.5 million) completing within the next twenty-four months.

On SCI-reportable federal service contracts above the $150,000 threshold, Inova reported invoiced revenue of $983 thousand across FY2023–FY2024 (FY2023: $490 thousand across 2.2 FTEs; FY2024: $493 thousand across 2.2 FTEs). Government-paid hourly rates on prime SCI contracts run from $58.73/hr at the 10th percentile to $90.82/hr at the median and $121.29/hr at the 90th percentile, with no subcontractor labor reported. Inova's federal grant portfolio includes recipient and sub-recipient roles supporting clinical research, biospecimen collection, and community health services. As a grant recipient, Inova received federal awards for HIV prevention services (Inova Juniper Program, National Center for HIV/AIDS Cooperative Agreement through March 2027), premature infant biospecimen collection for sepsis research (National Institute of General Medical Sciences R21/R33 award through June 2025), tranexamic acid timing and dosing for postpartum hemorrhage prevention (National Institute of Child Health and Human Development award through July 2028), cardiac transplantation immunosuppression biomarker research (NHLBI award through January 2030), and diabetes pregnancy research conference support (National Institute of Child Health and Human Development grant through July 2026). As a sub-recipient, Inova participates in military and civilian research networks anchored by the Henry M. Jackson Foundation, Columbia University, Georgetown University, Vanderbilt University Medical Center, Stanford University, and the Leland Stanford Junior University for cancer proteogenomics, cardiac rehabilitation, thyroid cancer decision support, gynecologic oncology research, and women's health HIV cohort studies. The organization's primary NAICS concentration falls under General Medical and Surgical Hospitals (28 awards), with secondary concentrations in All Other Professional, Scientific, and Technical Services (10 awards) and Biological Product Manufacturing (7 awards); top PSC codes reflect Medical-Other (13 awards), Support-Professional Other (19 awards), and Reference Laboratory Testing (10 awards) services.